Innovating Works

BacterOMIC

Financiado
Intelligence for precision therapies against antimicrobial resistance The first...
Intelligence for precision therapies against antimicrobial resistance The first diagnostic panel that probes all the clinically relevant antibiotics at once In the recent years, we have seen a drastic increase in the antibiotic resistance among bacterial pathogens. This is considered as one of the biggest threats to global health in the current era. The reason for that is inappropriat... In the recent years, we have seen a drastic increase in the antibiotic resistance among bacterial pathogens. This is considered as one of the biggest threats to global health in the current era. The reason for that is inappropriate use of antibiotics - patients are often treated with not optimal antibiotic that need to be changed after few days. Number of resistant microorganisms constantly elevates due to inappropriate use of antibiotics - patients are often treated with inappropriate drugs that need to be changed after few days if bacteria turns to be resistant. The reason for that is that current manual antibiotic resistance tests are time-consuming and laborious, while automatic antimicrobial tests offer analysis of a short lists of antibiotics. BacterOMIC is a response to the growing global threat of antibiotic resistance. We provide the first fully comprehensive rapid Antimicrobial Susceptibility Testing (AST) system to determine already in 4h which from all common antibiotics will be most successful in treating certain bacterial infection. Unlike current methods, our system also allows to investigate antimicrobial effect of not only single antibiotics but also combinations of multiple antibiotics – the future of infection disease treatment. Constantly growing antimicrobial susceptibility testing market was valued at EUR 2.4 billion in 2018 and is expected to reach EUR 3.1 billion by 2022 at the CAGR of 5.1%. With our clear business model we target pharmaceutical and biotechnology companies, contract research organizations, hospitals/private healthcare centers, and diagnostic laboratories. We have a network of partnerships across the EU (PL, FR, ES, CH, DE, and PT) and we are ready for rapid scale-up, with more than 30 million cumulative profit by 2025. We need SME Instrument phase 2 to optimize the design, prepare for mass production, validate the system in clinical trials, and certify it for successful commercialization. ver más
31/12/2021
3M€
Duración del proyecto: 26 meses Fecha Inicio: 2019-10-29
Fecha Fin: 2021-12-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2021-12-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
BACTEROMIC SPOLKA Z OGRANICZONA ODPOWIEDZIALN... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5